← back to search

Huamao Mark Lin

Takeda (United States) · US
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment, and Multiple Myeloma Research and Treatments.
h-index
24
citations
2,395
works
102
NIH funding
primary concept
Medicine
email

Recent publications

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
Journal of Clinical Oncology 2025cited by 22position: middledoi
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions
European Journal of Cancer 2022cited by 25position: middledoi
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
JAMA Oncology 2021cited by 289position: middledoi
Mobocertinib (TAK-788) in <i>EGFR</i> exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.
Journal of Clinical Oncology 2021cited by 29position: middledoi
P35.15 Molecular Epidemiology of KRAS G12C Mutations in Chinese Lung Cancer Patients
Journal of Thoracic Oncology 2021cited by 0position: middledoi
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer
JAMA Oncology 2018cited by 90position: middledoi
Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis
Amyloid 2018cited by 20position: middledoi
Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life
Supportive Care in Cancer 2015cited by 67position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Pasi A. Jänne · Harvard University3 papers (2021–2025)Danny Nguyen · City of Hope3 papers (2021–2025)Jianchang Lin · Florida State University3 papers (2021–2025)Veronica Bunn · Takeda (United States)2 papers (2021–2021)James Chih‐Hsin Yang · National Institutes of Health2 papers (2021–2021)Minal Mehta · Therapeutics Clinical Research2 papers (2021–2021)Gregory J. Riely · Weill Cornell Medicine2 papers (2021–2021)Tony Mok · South China University of Technology2 papers (2021–2025)Suresh S. Ramalingam · Emory University2 papers (2021–2021)Enriqueta Felip · Université Grenoble Alpes2 papers (2021–2021) · 2 papers (2021–2021)Tae Min Kim · Yeungnam University2 papers (2021–2021) · 2 papers (2021–2021)Sang-We Kim · Université Grenoble Alpes2 papers (2021–2021)Tarek Mekhail · AdventHealth Orlando2 papers (2021–2021)M.R. García Campelo · Universidade da Coruña2 papers (2021–2021) · 1 papers (2015–2015)Benjamin Besse · Institut Gustave Roussy1 papers (2025–2025)Caicun Zhou · Tongji University1 papers (2021–2021) · 1 papers (2021–2021)